William Blair Initiates Coverage of Illumina with 'Outperform' Rating | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Investment firm William Blair said today it has initiated coverage of Illumina's stock, giving it an "outperform" rating.

It also gave San Diego-based Illumina an "aggressive growth" company profile. Amanda Murphy, an analyst at William Blair, estimated a $1.06 earnings per share price for 2010, a $1.46 EPS for 2011, and a $1.93 EPS for 2012.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Rules and regulations governing genetic modifications of human embryos vary from country to country, Nature News says, but such work may take place despite restrictions.

Ancestry.com is eyeing an expansion into genomic risk assessments, the Verge reports.

In PNAS this week: adzuki bean genome, spontaneous mutation patterns in E. coli, and more.

An op-ed in the New York Times discusses banking of fecal samples to restore the gut microbiome.